Lobbying

Horizon Therapeutics USA's latest lobbying report covers Q1 2024, at $40K. Its first report covers Q4 2022; the issues it reports most are Health Issues and Taxation/Internal Revenue Code.

Horizon Therapeutics USA

Latest quarter
No record
Q3 2026 · 0 reports
Last 12 months
$0
Last 4 quarters
vs last quarter
No record
Q3 2026 against the quarter before
First report
Q4 2022
The first quarter a report named it

Lobbying by quarter

Horizon Therapeutics USA lobbying by quarter
Horizon Therapeutics USA lobbying by quarter
QuarterAmountReports
Q4 2022$1.3M2
Q1 2023$1.5M2
Q2 2023$1.1M2
Q3 2023$1.2M2
Q4 2023$90K2
Q1 2024$40K1
Q2 2024$00
Q3 2024$00
Q4 2024$00
Q1 2025$00
Q2 2025$00
Q3 2025$00
Q4 2025$00
Q1 2026$00
Q2 2026$00
Q3 2026$00

By issue

  • Health issues$2.6M · 9 reports
  • Taxation$2.5M · 4 reports
  • Medicare and Medicaid$80K · 4 reports

An issue's amount splits each report's amount equally over the issues the report lists.

Who was lobbied

  • HOUSE OF REPRESENTATIVES9 reports
  • SENATE9 reports
  • Executive Office of the President (EOP)4 reports
  • Centers For Medicare and Medicaid Services (CMS)1 reports
  • Health & Human Services, Dept of (HHS)1 reports

Firms it paid

Firm
In-houseHorizon Therapeutics USA$5M5 quarters
Jeffrey J. Kimbell & Associates$240K6 quarters

Former officials lobbying for it

Former position
JOHN HERZOGHealth Aide, Sen. Lamar Alexander; Special Assistant to the Assistant to the President for Legislative Affairs, Executive Office of the PresidentQ3 2023
JOHN R RAYLegislative Assistant, Rep. Mike KellyQ3 2023
KEITH STUDDARDLegislative Director, Rep. Marsha BlackburnQ3 2023
KELSEY CARLSONSpecial Assistant, National Security Council; Special Assistant, International Trade Administration, Dept of Commerce; Policy Advisor, Office of the Deputy Chief of Staff, Executive Office of the President; Confidential Assistant, Dept of CommerceQ3 2023

Lobbying reports

Filed by
24/02/15for Q1 2024Jeffrey J. Kimbell & Associates$40K
24/01/19for Q4 2023In-house$50K
24/01/18for Q4 2023Jeffrey J. Kimbell & Associates$40K
23/10/20for Q3 2023Jeffrey J. Kimbell & Associates$40K
23/10/20for Q3 2023In-house$1.2M
23/07/20for Q2 2023In-house$1.1M
23/07/20for Q2 2023Jeffrey J. Kimbell & Associates$40K
23/04/20for Q1 2023In-house$1.5M
23/04/17for Q1 2023Jeffrey J. Kimbell & Associates$40K
23/01/19for Q4 2022In-house$1.2M
23/01/18for Q4 2022Jeffrey J. Kimbell & Associates$40K